After attending the SLEEP conference where Jazz Pharmaceuticals presented a number of clinical updates, BMO Capital analyst Gary Nachman said Jazz demonstrated that its sleep pipeline is progressing well and robust, telling investors in a research note that he continues to believe solriamfetol remains underappreciated. Additionally, Nachman contends that the Xyrem franchise could possibly be bolstered with a pediatric indication, and there could be further upside down the road from JZP-258 and a once-nightly low-sodium form of oxybate. Nachman keeps an Outperfom rating on the shares with a $201 price target.